K
Kymera Therapeutics, Inc. (KYMR)
NGM – Real Time Price. Currency in USD
83.55
-0.55 (-0.65%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
83.55
-0.55 (-0.65%)
At close: May 12, 2026, 4:00 PM EDT
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Name | Position |
|---|---|
| Dr. Bruce L. Booth DPHIL, Ph.D. | Co-Founder & Independent Chairman |
| Dr. Jared A. Gollob M.D. | Chief Medical Officer |
| Dr. Jeremy G. Chadwick Ph.D. | Chief Operating Officer |
| Dr. Neil Graham M.D., M.P.H., MBBS | Chief Development Officer |
| Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, CEO & Director |
| Mr. Brian R. Adams J.D. | Chief Legal Officer & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | 8-K | kymr-20260430.htm |
| 2026-04-30 | 10-Q | kymr-20260331.htm |
| 2026-04-29 | DEFA14A | kymr_defa14a_2025.htm |
| 2026-03-27 | 8-K | d122194d8k.htm |
| 2026-02-26 | 10-K | kymr-20251231.htm |
| 2026-01-13 | 8-K | d78447d8k.htm |
| 2025-12-10 | 8-K | d89982d8k.htm |
| 2025-11-04 | 10-Q | kymr-20250930.htm |
| 2025-09-03 | 8-K | d94060d8k.htm |
| 2025-08-11 | 8-K | kymr-20250811.htm |
| Mr. Bruce N. Jacobs CFA | Chief Financial Officer |
| Mr. Noah Goodman M.B.A. | Chief Business Officer |
| Ms. Justine E. Koenigsberg | Vice President of Investor Relations |
| Ms. Karen Weisbach | Head of People & Culture |